Mobbs B G, Johnson I E, DeSombre E R, Toth J, Hughes A
Cancer Res. 1987 May 15;47(10):2645-51.
In order to assess prostatic tissue as a target for receptor-mediated estrogen action, we have examined the regulation of estrogen (ER) and progestin receptors (PgR) by estrogen, antiestrogen, and progesterone in cytosolic and nuclear fractions of the R3327H (Dunning) prostatic adenocarcinoma of the rat. Twenty micrograms diethylstilbestrol (DES) with or without 800 micrograms tamoxifen (Tam) were injected s.c. in oil 5 times weekly for 2 weeks. Controls were given oil only. Estrogen receptor assays were carried out using [3H]estradiol and a hydroxylapatite exchange method. Progestin receptors were assayed using [3H]R5020 and dextran-coated charcoal to separate free and bound steroid. All binding data were evaluated by using Scatchard analysis. Treatment with DES depleted cytosolic ER, promoted association of ER with the nuclear fraction, and concomitantly increased PgR concentrations in amounts proportional to nuclear ER. Treatment with Tam alone resulted in higher nuclear ER concentrations than treatment with DES, but induced only one-fifth the amount of PgR. Treatment with DES plus Tam resulted in similar nuclear ER concentrations as with Tam alone, but PgR concentrations were intermediate between those observed with DES alone and Tam alone. Thus Tam exhibited both estrogenic and antiestrogenic properties. In this experiment, the same cytosolic and nuclear extracts were also assayed for ER by using monoclonal antibodies to the receptor in an enzyme immunoassay. No significant differences were observed between the results obtained by the radioligand and enzyme immunoassay methods in the cytosol and nuclear fractions from the control and DES-treated tumors. However in both Tam-treated groups, the ER values obtained by the enzyme immunoassay method were significantly higher than those obtained by the radioligand method in both cytosolic and nuclear fractions. This confirms the observations made by others in female target organs, that monoclonal antibody to ER reacts differently with the Tam-bound ER complex than with the estradiol-bound ER complex. In a separate experiment, administration of progesterone with DES decreased the concentration of nuclear ER to less than one-half that observed after administration of DES alone, with proportional decreases in both cytosolic and nuclear PgR. All these observations indicate that the control of ER and PgR concentrations in this prostatic tumor is identical to that observed in female rat target organs. Use of an immunohistochemical method for the detection of ER in frozen sections indicated that the receptor was localized in the glandular epithelium in both control and DES-treated tumors.
为了评估前列腺组织作为受体介导的雌激素作用靶点,我们研究了雌激素、抗雌激素和孕酮对大鼠R3327H(邓宁)前列腺腺癌胞质和核部分中雌激素受体(ER)和孕激素受体(PgR)的调节作用。每周5次皮下注射含或不含800微克他莫昔芬(Tam)的20微克己烯雌酚(DES),共2周。对照组仅给予油剂。使用[3H]雌二醇和羟基磷灰石交换法进行雌激素受体测定。使用[3H]R5020和葡聚糖包被活性炭分离游离和结合类固醇来测定孕激素受体。所有结合数据均通过Scatchard分析进行评估。用DES处理可使胞质ER减少,促进ER与核部分结合,并同时使PgR浓度按与核ER成比例的量增加。单独用Tam处理导致核ER浓度高于用DES处理,但诱导的PgR量仅为五分之一。用DES加Tam处理导致核ER浓度与单独用Tam处理相似,但PgR浓度介于单独用DES和单独用Tam观察到的浓度之间。因此,Tam具有雌激素和抗雌激素特性。在该实验中,还使用针对该受体的单克隆抗体通过酶免疫测定法对相同的胞质和核提取物进行ER测定。在对照和DES处理肿瘤的胞质和核部分中,放射性配体法和酶免疫测定法获得的结果之间未观察到显著差异。然而,在两个Tam处理组中,酶免疫测定法获得的ER值在胞质和核部分均显著高于放射性配体法获得的值。这证实了其他人在雌性靶器官中所做的观察,即针对ER的单克隆抗体与Tam结合的ER复合物的反应不同于与雌二醇结合的ER复合物。在另一个实验中,DES与孕酮联合给药使核ER浓度降至单独给予DES后观察到的浓度的一半以下,胞质和核PgR也成比例降低。所有这些观察结果表明,该前列腺肿瘤中ER和PgR浓度的控制与在雌性大鼠靶器官中观察到的相同。使用免疫组织化学方法检测冰冻切片中的ER表明,在对照和DES处理的肿瘤中,该受体均定位于腺上皮。